Text-only version
LawWeb
Directory
Contact Us
Email
News
&
Events
Media Guide
C'ville
UVA
About
Academics
Admissions
Students
Faculty
Library
Alumni
&
Giving
Public Service
Career Services
Academics
Concentrations
Dual-Degree Programs
Clinical Programs
Academic Journals
Current Courses
J.D. Curriculum
Academic Policies
Academic Calendar
Student Records
Externships
Law Studies Abroad
Institutes and Centers
Degree Programs
Awards and Honors
The Honor System
Curricular Programs
Law & Business
Law and Public Service
International Law
Legal and Constitutional History
Criminal Law
Human Rights
Center for the Study of Race and Law
Environmental and Land Use Law
Immigration Law
Intellectual Property
Health Law
Public Policy and Regulation
Law and Humanities
Animal Law
Fall 2012
Law No.: LAW8659
Sched. No.: 112820602
Drug Product Liability Litigation: Principles and Practice*
Section 1
X
Grossi, Peter T.
Administrative Information:
During SIS enrollment, check
on SIS
for real-time enrollment numbers
Days, Times (Room):
M, 1600-1815 (SL290)
Credits:
3
Type:
Seminar
Capacity:
30
**This information is current as of
05/21/2013 06:18:01 AM
**
Current Enrollment:
30
**This information is current as of
05/21/2013 06:18:01 AM
**
Course Description:
More product liability lawsuits are filed against prescription drug manufacturers than against all other industries combined. As one legal scholar put it, the pharmaceutical industry is now “in tobacco-land in terms of how much people hate it,” and drug product liability litigation is now a “growth industry.”
This course will consider the theory and practice of such lawsuits before, and now after, the Supreme Court’s recent landmark decision in
Wyeth v. Levine
(2009). At the outset, we will focus on the similarities and differences between such litigation and other product liability cases, using the “Phen-Fen” cases tried by the instructor as a model, and on the special context of FDA regulation. We will then consider the legal principles governing such lawsuits, such as inadequate warning; the learned intermediary doctrine; and medical causation. As part of each class, we will review the manner in which those issues were presented to a jury using the edited record of a recent pharma products trial.
The course will also consider the practical application of those doctrines, including the problems when doctors are witnesses; discovery strategies; and techniques to present complex information to juries. For the final class, each student will prepare one short portion of an opening jury statement, based on the edited trial record they have been reviewing, which will then be combined and presented to a “jury” recruited from Charlottesville residents.
COURSE REQUIREMENT: A short “bench memo” due Week 7; a 4-5 page section of the final jury presentation due Week 11; class participation. (N.B. The oral component of the jury presentation will not be graded -- only the individual written components will be evaluated.)
This course is on the professional skills course list.